

PRESS INFORMATION

PRESS INFORMATIONAugust 31, 2018 || page 1 | 3

Fraunhofer IZI and Novartis Continue Successful Collaboration with CAR-T Cell Therapy

Novartis and Fraunhofer IZI announced today that a further agreement has been concluded between Novartis and the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig for the manufacture of the CAR (chimeric antigen receptor)-T cell therapy for patients in Europe over the next few years. The collaboration that began back in 2015 to manufacture CAR-T cell therapies for patients taking part in clinical trials initiated by Novartis is therefore being successfully expanded and continued.

Fraunhofer IZI is a key manufacturing and development site here for the cell therapy Kymriah® (CTL019) provided to patients in Europe taking part in respective clinical trials and Compassionate Use Programs.

On August 27, 2018, Novartis announced that the therapy had been approved by the European approval authority EMA (European Medicines Agency)(1). Over the next few years, prescription-only T-cell therapies will now also be manufactured on an interim basis in the Main Department of GMP Cell and Gene Therapy at Fraunhofer IZI, alongside investigational medicinal products.

At a joint press event, Novartis, Fraunhofer IZI and investigators from Frankfurt and Cologne university hospitals discussed the mode of action, the manufacturing process and their experiences so far from the clinical trials.



Production of CAR-T cell therapy in the clean room of Fraunhofer IZI
Photo © Fraunhofer IZI

Editor

Jens Augustin | Fraunhofer Institute for Cell Therapy and Immunology IZI | Phone +49 341 35536-9320 |
Perlickstr. 1 | 04103 Leipzig | Germany | www.izi.fraunhofer.de | jens.augustin@izi.fraunhofer.de

About the CAR-T cell therapy and Kymriah® ^{2,3,4,5}

PRESS INFORMATIONAugust 31, 2018 || page 2 | 3

The CAR-T cell therapy is a new type of cancer immunotherapy. It uses T cells found in the patient's body to fight certain types of cancer. In order to do this, the cells are extracted by leukapheresis and then genetically reprogrammed in vitro in such a way that they can use their chimeric antigen receptor to recognize cancer cells and other cells that have a specific antigen on their surface. Following lymphodepleting chemotherapy, the reprogrammed cells are fed back to the patient through an infusion. The cells then multiply and can trigger the immune response.

In August 2017, the first CAR (chimeric antigen receptor)-T cell therapy became available in the USA in the form of Kymriah® (CTL019/tisagenlecleucel). Kymriah® was granted FDA approval for children and young adults up to the age of 25 years who have acute lymphocytic B-cell leukemia that is therapy-refractory or has relapsed at least twice. Approval was subsequently granted in May 2018 for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. On August 27, 2018, Novartis announced that it had received approval from the European Medicines Agency for both of these indications. The therapy is an innovative one-time immunotherapy which uses the patient's own genetically modified cells in the fight against cancer cells. CTL019 uses the 4-1BB costimulatory domain as part of the chimeric antigen receptor in order to increase the expansion and persistence of the cells.

¹⁾ Further information on the approval of Kymriah® can be found in the [press release published by Novartis on August 27, 2018](#).

²⁾ Abken H. CAR-T Zellen: Wie Designer-Immunzellen gegen den Krebs scharfgemacht werden können. *Trillium Immunologie* 2017; 1(1):43-47.

³⁾ Tran E et al. A Milestone for CAR T Cells. *New Engl J Med* 2017. DOI: 10.1056/NEJMe1714680.

⁴⁾ Information on Kymriah provided by the FDA. Available online at www.fda.gov

⁵⁾ CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications. Köhl U, Arsenieva S, Holzinger A, Abken H, *Hum Gene Ther.* 2018 May; 29(5):559-568

FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY IZI

The Fraunhofer Institute for Cell Therapy and Immunology IZI

PRESS INFORMATION

August 31, 2018 || page 3 | 3



The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute's main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharmaceuticals and medical engineering. The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs, Diagnostics and Biosystems Technology. Its areas of competence lie in cell biology, immunology, drug biochemistry, biomarker, bioanalytics and bioproduction as well as process development and automation. In these areas, research specifically focusses on the indications oncology, neuropathology, autoimmune and inflammatory diseases as well as infectious diseases and regenerative medicine.

The **Fraunhofer-Gesellschaft** is the leading organization for applied research in Europe. Its research activities are conducted by 72 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of more than 25,000, who work with an annual research budget totaling 2.3 billion euros. Of this sum, almost 2 billion euros is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft's contract research revenue is derived from contracts with industry and from publicly financed research projects. International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.

Further contact

Dr. Gerno Schmiedeknecht | Phone +49 341 35536-9705 | gerno.schmiedeknecht@izi.fraunhofer.de | Fraunhofer Institute for Cell Therapy and Immunology IZI | www.izi.fraunhofer.de/en